Articles Tagged With: remdesivir
-
COVID-19: Beware Remdesivir Resistance
Researchers reported two immunosuppressed renal transplant recipients with persistent SARS-CoV-2 infection in association with the new emergence of mutations in RNA-dependent RNA polymerase after remdesivir treatment.
-
COVID-19: Beware Remdesivir Resistance
Hogan and colleagues reported two immunosuppressed renal transplant recipients with persistent SARS-CoV-2 infection in association with the new emergence of mutations in ribonucleic acid (RNA)-dependent RNA polymerase after remdesivir treatment.
-
Study: Interferon Does Not Help Hospitalized COVID-19 Patients
When combined with remdesivir, the multiple sclerosis drug did not produce clinical benefit.
-
Q&A: Data Safety Monitoring Board Experts Explain Role in Clinical Research
Data safety monitoring boards (DSMBs) have played a big role in delivering vaccines and treatments to the public faster in the past 18 months. DSMBs reviewed results and safety data of the various studies involving treatments and vaccines for COVID-19. IRB Advisor asked two scientists about how DSMB work has helped improve research protections during the pandemic. -
The Effect of Antiviral Drugs on COVID-19 Outcomes and Mortality
The WHO Solidarity Trial Consortium found that remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had “little or no effect” on relevant outcomes. -
Treatment of COVID-19 Patients with Remdesivir, Hydroxychloroquine, Lopinavir, or Interferon Beta-1a
None of the four drugs studied was superior to placebo.
-
A Review of Current Therapeutics for Severe COVID-19 Pneumonia
The aim of this special feature is to review therapeutic options for hospitalized patients with COVID-19 pneumonia.
-
Remdesivir Injection (Veklury)
Remdesivir’s benefit appears to be modest, but may be better for those receiving low-flow oxygen.
-
Early Data on Remdesivir for Severe COVID-19: A Promising Start?
In this group of patients hospitalized with severe COVID-19, most of whom required invasive ventilation, 68% showed clinical improvement after treatment with remdesivir on a compassionate-use basis.
-
Biometrics Expert Discusses Data Integrity for COVID-19 Clinical Trials
The first remdesivir double-blind, placebo-controlled clinical trial for treating COVID-19 was published recently in Lancet. A member of the trial’s data safety monitoring board is Weichung Shih, PhD. Shih discussed the role of biostatisticians in protecting data integrity for clinical trials and the challenges during the COVID-19 pandemic.